Al Sandrock
Putting Biogen's Aduhelm crisis behind him, Al Sandrock grabs CEO role at gene therapy player to lead turnaround mission
Al Sandrock’s re-entry back to biotech comes just as abruptly as his last exit.
The Biogen vet — who retired last November as R&D chief after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
